NCT05963126 Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients
| NCT ID | NCT05963126 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Ostrava |
| Condition | Arterial Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-07-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.
Eligibility Criteria
Inclusion Criteria: * Arterial hypertension treated by at least one antihypertensive agent Exclusion Criteria: * Diabetes mellitus of any type, defined as fasting glucose \>7,0 mmol/l or any glycemia \>11,0 mmol/l, or HbA1c\>48 mmol/mol * Decompensated arterial hypertension defined as office blood pressure \>180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM) * Patient with renal replacement therapy * Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening * Acute infection defined as C-Reactive Protein (CRP) \>50 mg/l * Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) \>10 µkat/l * Terminal incurable illness
Contact & Investigator
Zdeněk Ramík, MD
PRINCIPAL INVESTIGATOR
University Hospital Ostrava
Frequently Asked Questions
Who can join the NCT05963126 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Arterial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05963126 currently recruiting?
Yes, NCT05963126 is actively recruiting participants. Contact the research team at jiri.hyncica@fno.cz for enrollment information.
Where is the NCT05963126 trial being conducted?
This trial is being conducted at Ostrava, Czechia.
Who is sponsoring the NCT05963126 clinical trial?
NCT05963126 is sponsored by University Hospital Ostrava. The principal investigator is Zdeněk Ramík, MD at University Hospital Ostrava. The trial plans to enroll 200 participants.